Interim results from a Phase I clinical trial indicate that VERVE-102, an experimental gene-editing treatment, effectively reduces low-density lipoprotein (LDL) levels in patients with high cholesterol.

第一期臨床試驗的中期結果顯示，一種實驗性基因編輯治療方法 VERVE-102，能有效降低高膽固醇患者體內的低密度脂蛋白 (LDL) 水平。

The therapeutic mechanism of VERVE-102 utilizes mRNA-based nanoparticles to deliver an adenine base-editor protein and guide RNA to hepatic cells. This machinery facilitates a precise genomic alteration in the PCSK9 gene, inducing a premature stop signal that prevents the production of the PCSK9 enzyme. Because the PCSK9 enzyme typically promotes the degradation of LDL receptors, its inactivation enhances the liver's capacity to clear LDL from the bloodstream, mimicking a naturally occurring genetic deficiency associated with reduced cardiovascular risk.

VERVE-102 的治療機制是利用基於 mRNA 的奈米顆粒，將腺嘌呤鹼基編輯蛋白與指南 RNA 傳送到肝細胞。此機制可促使 PCSK9 基因產生精確的基因組改變，誘導出提前停止信號，從而阻止 PCSK9 酶的產生。由於 PCSK9 酶通常會促進 LDL 受體的分解，因此將其滅活可增強肝臟清除血液中 LDL 的能力，模擬一種與降低心血管風險相關的天然基因缺陷。

Stakeholder positioning is centered on the mitigation of patient non-compliance associated with chronic pharmacological interventions, such as statins or recurring injections. The trial, conducted by Verve Therapeutics (now a subsidiary of Eli Lilly), involved 35 participants with genetic predispositions to hypercholesterolemia or early-onset cardiovascular disease. Data published in the New England Journal of Medicine demonstrate a dose-dependent response: the lowest dose (0.3 mg/kg) resulted in a 9% LDL reduction, whereas the highest dose (1 mg/kg) achieved a 62% reduction. While the trial reported a transient elevation of liver enzymes, no serious adverse events occurred.

利益相關者的定位集中在緩解患者對長期藥物治療（如他汀類藥物或反覆注射）不配合的問題。由 Verve Therapeutics（現為禮來公司 Eli Lilly 之子公司）進行的試驗，涉及 35 位具有高膽固醇血症或早發性心血管疾病基因傾向的參與者。發表於《新英格蘭醫學雜誌》的數據顯示出劑量依賴性反應：最低劑量 (0.3 mg/kg) 導致 LDL 降低 9%，而最高劑量 (1 mg/kg) 則達到 62% 的降幅。儘管試驗報告指出肝酶有暫時性升高，但未發生嚴重的不良事件。

Institutional confidence in the durability of the treatment is supported by the biological turnover rate of hepatic cells and animal model data extending to three years. Should the efficacy be sustained over a twenty-year horizon, the estimated risk of cardiovascular disease could be reduced by 50%. Consequently, the U.S. Food and Drug Administration has granted the therapy Fast Track designation.

機構對治療持久性的信心，是基於肝細胞的生物代謝率以及長達三年的動物模型數據。若療效能在二十年內維持，預計心血管疾病的風險可降低 50%。因此，美國食品藥藥局 (FDA) 已授予該療法「快速通道」資格。

VERVE-102 has demonstrated preliminary safety and efficacy in a small cohort, with further large-scale trials required to validate its long-term clinical utility.

VERVE-102 在一個小型樣本組中證明了初步的安全性與療效，但仍需要進一步的大規模試驗以驗證其長期臨床實用性。